Roivant Sciences Ltd (NASDAQ: ROIV) has a higher price-to-earnings ratio of 1.87x compared to its average ratio, The 36-month beta value for ROIV is at 1.29. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ROIV is 376.90M, and currently, shorts hold a 11.54% of that float. The average trading volume for ROIV on January 13, 2025 was 4.65M shares.
ROIV) stock’s latest price update
Roivant Sciences Ltd (NASDAQ: ROIV)’s stock price has plunge by -0.42relation to previous closing price of 10.63. Nevertheless, the company has seen a -9.45% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-04 that Roivant Sciences leverages its “Vant” model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant’s sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability.
ROIV’s Market Performance
Roivant Sciences Ltd (ROIV) has seen a -9.45% fall in stock performance for the week, with a -12.45% decline in the past month and a -10.83% plunge in the past quarter. The volatility ratio for the week is 3.47%, and the volatility levels for the past 30 days are at 2.82% for ROIV. The simple moving average for the past 20 days is -9.06% for ROIV’s stock, with a -6.99% simple moving average for the past 200 days.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with Wolfe Research repeating the rating for ROIV by listing it as a “Outperform.” The predicted price for ROIV in the upcoming period, according to Wolfe Research is $17 based on the research report published on February 15, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $20. The rating they have provided for ROIV stocks is “Overweight” according to the report published on January 05th, 2024.
Deutsche Bank gave a rating of “Buy” to ROIV, setting the target price at $14 in the report published on December 12th of the previous year.
ROIV Trading at -10.46% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.92% of loss for the given period.
Volatility was left at 2.82%, however, over the last 30 days, the volatility rate increased by 3.47%, as shares sank -12.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.46% lower at present.
During the last 5 trading sessions, ROIV fell by -9.32%, which changed the moving average for the period of 200-days by +5.16% in comparison to the 20-day moving average, which settled at $11.64. In addition, Roivant Sciences Ltd saw -10.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ROIV starting from Venker Eric, who sale 176,900 shares at the price of $11.82 back on Dec 27 ’24. After this action, Venker Eric now owns 668,680 shares of Roivant Sciences Ltd, valued at $2,090,958 using the latest closing price.
Venker Eric, the President & COO of Roivant Sciences Ltd, sale 177,704 shares at $11.54 during a trade that took place back on Dec 30 ’24, which means that Venker Eric is holding 740,976 shares at $2,050,704 based on the most recent closing price.
Stock Fundamentals for ROIV
Current profitability levels for the company are sitting at:
- 34.48 for the present operating margin
- 0.89 for the gross margin
The net margin for Roivant Sciences Ltd stands at 38.27. The total capital return value is set at 0.77. Equity return is now at value 159.08, with 117.35 for asset returns.
Currently, EBITDA for the company is 4.31 billion with net debt to EBITDA at -0.44. When we switch over and look at the enterprise to sales, we see a ratio of 46.14. The receivables turnover for the company is 5.54for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.43.
Conclusion
In conclusion, Roivant Sciences Ltd (ROIV) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
